Bispecific antibodies (BsAbs) are a promising therapeutic approach aiming to enhance the efficacy of biologics by targeting multiple pathways simultaneously. However, the pharmacokinetic (PK) behavior of BsAbs can vary widely during the early stages of discovery. Improving the pharmacokinetic developability of BsAbs involves optimizing interactions with the neonatal Fc receptor (FcRn) and addressing undesirable physiochemical properties. This study investigated the PK of two related single-chain variable fragment (scFv)-based BsAbs in cynomolgus monkeys, revealing significant differences in clearance rates attributed to variations in FcRn interactions and physiochemical properties.
BsAbs have gained recognition as a valuable therapeutic modality, with numerous candidates in clinical development across various disease indications. These molecules can engage multiple disease pathways, offering enhanced efficacy and potential novel functionalities. Despite their therapeutic promise, the translation of BsAbs into effective medicines has been slower compared to monoclonal antibodies (mAbs). Challenges such as incomplete understanding of mechanism of action, undefined exposure-response profiles, and potential immunogenicity have hindered the clinical success of BsAbs.
To address poor pharmacokinetics, preclinical physiochemical characterization strategies have been employed to enhance the stability and reduce nonspecific interactions of mAbs. These approaches aim to optimize exposure profiles to support dosing regimens effectively. The current study extends these strategies to BsAbs, particularly those utilizing IgG-extracellular domain (ECD) and IgG-scFv formats. Physiochemical assessments revealed differences in solubility, isoelectric points, thermal stability, and charge interactions between the two BsAbs, impacting their pharmacokinetic profiles.
Evaluation of FcRn interactions demonstrated distinct differences between the two BsAbs, with one showing a higher rate of clearance due to poor release from FcRn at neutral pH. The study integrated in vitro physiochemical data with in vivo pharmacokinetics to elucidate the factors influencing the disposition of BsAbs. Notably, the study highlighted the importance of balancing non-target-related factors affecting BsAb clearance and the impact of BsAb format on these parameters.
In-depth analyses included the expression and purification of BsAbs, physiochemical characterizations (solubility, isoelectric points, thermal stability, charge interactions), and FcRn interaction studies. Pharmacokinetic assessments in cynomolgus monkeys revealed significant differences in clearance rates and elimination half-lives between the two BsAbs, indicating the influence of FcRn interactions on in vivo behavior. Biodistribution studies further elucidated tissue distribution and elimination kinetics, providing mechanistic insights into the observed pharmacokinetic disparities.
Overall, this case study underscores the importance of integrating physiochemical properties and FcRn interactions with in vivo pharmacokinetics to optimize the developability and disposition profiles of BsAbs. By identifying key factors impacting the clearance of BsAbs, this study contributes to enhancing the understanding of non-target-related mechanisms influencing the pharmacokinetics of bispecific antibodies.
- BsAbs offer a promising therapeutic strategy by targeting multiple disease pathways simultaneously.
- Optimization of physiochemical properties and FcRn interactions is crucial for improving the pharmacokinetic developability of BsAbs.
- Integration of in vitro physiochemical data with in vivo pharmacokinetics provides valuable insights into the factors influencing the disposition of BsAbs.
- Disparities in clearance rates between related BsAbs underscore the importance of balancing non-target-related factors in BsAb design and development.
Tags: clinical trials, regulatory, chromatography, protein engineering, formulation
Read more on pmc.ncbi.nlm.nih.gov